Alessandro Doria, Ph.D., M.D.
Co-Author
This page shows the publications co-authored by Alessandro Doria and Hetal Shah.
Connection Strength
3.391
-
Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. Diabetes Care. 2018 02; 41(2):348-355.
Score: 0.737
-
Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. Diabetes Care. 2016 Nov; 39(11):1915-1924.
Score: 0.674
-
Association of the 1q25 Diabetes-Specific Coronary Heart Disease Locus With Alterations of the ?-Glutamyl Cycle and Increased Methylglyoxal Levels in Endothelial Cells. Diabetes. 2020 10; 69(10):2206-2216.
Score: 0.221
-
Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes. J Am Coll Cardiol. 2020 06 16; 75(23):2995-2996.
Score: 0.220
-
PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. Diabetes. 2020 04; 69(4):771-783.
Score: 0.214
-
A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. Diabetes. 2019 08; 68(8):1649-1662.
Score: 0.204
-
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. Diabetes Care. 2018 Nov; 41(11):2404-2413.
Score: 0.195
-
Increase in apoliporotein-A2 Levels is associated with lower cardiovascular risk in the accord lipid trial. Atherosclerosis. 2017 Aug; 263:e43.
Score: 0.180
-
Genetic Variant at the GLUL Locus Predicts All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes. 2015 Jul; 64(7):2658-63.
Score: 0.152
-
The type 2 diabetes and insulin-resistance locus near IRS1 is a determinant of HDL cholesterol and triglycerides levels among diabetic subjects. Atherosclerosis. 2011 May; 216(1):157-60.
Score: 0.115
-
Diabetes mellitus correlates with increased biological age as indicated by clinical biomarkers. Geroscience. 2022 02; 44(1):415-427.
Score: 0.061
-
A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. Diabetes Care. 2021 06; 44(6):1410-1418.
Score: 0.058
-
Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. Diabetes Care. 2021 01; 44(1):164-173.
Score: 0.056
-
Estimation of Mortality Risk in Type 2 Diabetic Patients (ENFORCE): An Inexpensive and Parsimonious Prediction Model. J Clin Endocrinol Metab. 2019 10 01; 104(10):4900-4908.
Score: 0.052
-
A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 2019 05; 25(5):805-813.
Score: 0.051
-
Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. Diabetes. 2018 07; 67(7):1428-1440.
Score: 0.047
-
Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. Clin Pharmacol Ther. 2018 04; 103(4):712-721.
Score: 0.046
-
Variants in ANGPTL4 and the Risk of Coronary Artery Disease. N Engl J Med. 2016 12 08; 375(23):2304-2305.
Score: 0.043
-
Joint effect of insulin signaling genes on insulin secretion and glucose homeostasis. J Clin Endocrinol Metab. 2013 Jun; 98(6):E1143-7.
Score: 0.034
-
The 9p21 coronary artery disease locus and kidney dysfunction in patients with Type 2 diabetes mellitus. Nephrol Dial Transplant. 2012 Dec; 27(12):4411-3.
Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.